Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) (Restore)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02090114
Recruitment Status : Recruiting
First Posted : March 18, 2014
Last Update Posted : May 14, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Brief Summary:
Single-arm, single site, open label study of the effects of parenteral testosterone followed by enzalutamide or abiraterone or castration-only therapy in men with metastatic CRPC who previously progressed on one of these forms of therapy. The study will enroll three cohorts of patients: men with metastatic CRPC who have progressed on enzalutamide (Cohort A); men with metastatic CRPC who have progressed on abiraterone acetate (Cohort B); and men with metastatic CRPC who have progressed on first line castration-only therapy (Cohort C).

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Testosterone cypionate Drug: Testosterone Enanthate Drug: Abiraterone acetate Drug: Enzalutamide (Cohort A = CLOSED TO ACCRUAL) Phase 2

Detailed Description:
The trial will enroll up to 90 patients, 30 for each cohort. Eligible patients will continue on androgen ablative therapy with LHRH agonist (i.e. Zoladex, Trelstar, Eligard or Lupron) if not surgically castrated to suppress endogenous testosterone production. Patients will also receive intramuscular injection with either testosterone cypionate or testosterone enanthate at a dose of 400 mg every 28 days. This dosing scheme was designed to produce rapidly fluctuating serum testosterone levels from the supraphysiologic to the near-castrate range (i.e. Bipolar Androgen Therapy [BAT]). Assessments for response to testosterone will be made approximately every 3 months. Upon displaying evidence of progression, patients will then go on to receive either abiraterone or enzalutamide (whichever agent they had previously progressed on prior to study enrollment) or remain on LHRH agonist therapy and receive no additional androgen ablative hormonal therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) Followed by Enzalutamide or Abiraterone Post-BAT in Men With Prostate Cancer Progressing on Combined Androgen Ablative Therapies
Study Start Date : June 2014
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : April 2021


Arm Intervention/treatment
Experimental: Post-abiraterone or post-enzalutamide or post-castration only
Men with castration-resistant prostate cancer who have progressed on either abiraterone or enzalutamide or castration-only therapy will be enrolled to this arm. These patients will then receive intramuscular injections with testosterone cypionate 400 mg every 28 days or testosterone enanthate 400 mg every 28 days. Upon progression on testosterone cypionate or enanthate, men will be retreated with either abiraterone 1000 mg by mouth daily or enzalutamide 160 mg by mouth daily, depending on which drug they previously received or remain on LHRH agonist alone for one month to re-establish a castrate level of testosterone (<50 ng/dL).
Drug: Testosterone cypionate
DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
Other Name: DEPO-Testosterone Injection

Drug: Testosterone Enanthate
Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
Other Name: Delatestryl

Drug: Abiraterone acetate
Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.
Other Name: Zytiga

Drug: Enzalutamide (Cohort A = CLOSED TO ACCRUAL)
XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.
Other Name: Xtandi




Primary Outcome Measures :
  1. Prostate Specific Antigen (PSA) response to Bipolar Androgen Therapy (BAT) [ Time Frame: up to 18 months ]
    Number of participants with ≥50% PSA reduction from pre-BAT baseline level

  2. PSA response to enzalutamide or abiraterone acetate post Bipolar Androgen Therapy [ Time Frame: up to 24 months ]
    Number of participants with ≥50% PSA reduction after enzalutamide or abiraterone acetate post-BAT from baseline

  3. PSA response to castrate levels of testosterone post Bipolar Androgen Therapy [ Time Frame: up to 18 months ]
    Number of participants who return to castrate levels of testosterone post Bipolar Androgen Therapy


Secondary Outcome Measures :
  1. PSA progression on enzalutamide or abiraterone acetate or castrate levels post-BAT [ Time Frame: up to 18 months ]
    Time to PSA progression on enzalutamide or abiraterone acetate or return to castrate levels of testosterone post-BAT

  2. PSA progression on BAT (Bipolar Androgen Therapy ) [ Time Frame: up to 18 months ]
    Time to PSA progression on BAT

  3. Disease response as defined by RECIST 1.1 (soft tissue lesions) and PCWG2 criteria (bone lesions) [ Time Frame: up to 18 months ]
    Number of participants with complete or partial response post-BAT and post-treatment with enzalutamide or abiraterone acetate as defined by RECIST 1.1 (for soft tissue lesions) and PCWG2 criteria (for bone disease), or return to castration-only post-BAT.

  4. Initiation of docetaxel chemotherapy [ Time Frame: up to 18 months ]
    Time to initiation of docetaxel chemotherapy

  5. Quality of Life (QoL) as assessed by FACIT-F score [ Time Frame: Change from baseline to 18 months ]
    Functional Assessment of Chronic Illness Therapy, Fatigue Subscale (FACIT-F) assesses Fatigue with a total score range of 0-52, with a higher score reflecting better QoL.

  6. Safety and Tolerability as assessed by Number of Participants with Adverse Events [ Time Frame: 18 months ]
    Number of participants who experience adverse events, as defined by NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

  7. Fasting glucose [ Time Frame: 18 months ]
    Fasting blood glucose level (mg/dL)

  8. Hemoglobin A1c [ Time Frame: 18 months ]
    Serum percent glycosylated hemoglobin (Hemoglobin A1C)

  9. Fasting insulin [ Time Frame: 18 months ]
    Fasting insulin levels

  10. Serum C-telopeptide [ Time Frame: 18 months ]
    Serum C-telopeptide levels (pg/mL)

  11. Osteocalcin [ Time Frame: On average at 18 months ]
    Serum Osteocalcin levels (ng/mL)

  12. Effect of treatment with testosterone and abiraterone acetate or enzalutamide on Bone Scan with SPECT CT [ Time Frame: 18 months ]
    Effect of treatment with testosterone and abiraterone acetate or enzalutamide as determined by Change in Tc-99 MDP uptake on quantitative Bone Scan with SPECT CT

  13. Quality of Life (QoL) as assessed by RANDSF-36 [ Time Frame: Change from baseline to 18 months ]
    RAND 36-Item Short Form (RANDSF-36) assesses physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, general health perceptions, and perceived change in health with a total score range of 0-100, with a higher score reflecting better QoL.

  14. Quality of Life (QoL) as assessed by BPI [ Time Frame: Change from baseline to 18 months ]
    Brief Pain Inventory (BPI) assesses the severity of pain and its impact on functioning with scales ranging from 0-10, with a higher score indicating a higher level of pain.

  15. Quality of Life (QoL) as assessed by IIEF [ Time Frame: Change from baseline to 18 months ]
    International Index of Erectile Function (IIEF-5) is a diagnostic tool for erectile dysfunction, with a total score range of 5-25, with the lowest score indicating a higher degree of dysfunction.

  16. Quality of Life (QoL) as assessed by PANAS [ Time Frame: Change from baseline to 18 months ]
    Positive and Negative Affect Schedule (PANAS) is a self-report measure that is made up of two mood scales, one measuring positive affect and the other measuring negative affect, with a total score range from 10-50 with a higher score on the positive scale indicating greater levels of positive affect and a lower score on the negative scale indicating less of a negative affect.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Performance status ≤2
  2. Age ≥18 years
  3. Histologically-confirmed adenocarcinoma of the prostate
  4. Progressing on continuous androgen ablative therapy (either surgical castration or LHRH agonist).
  5. Documented castrate level of serum testosterone (<50 ng/dl).
  6. For Cohorts A and B, patients must have progressed on prior treatment with enzalutamide or abiraterone acetate + prednisone (by PSA criteria or radiographically).
  7. For castration-only Cohort C, patients must have developed castrate resistant prostate cancer after progressing on first line hormone therapy with either surgical castration or LHRH agonist or LHRH agonist plus an anti-androgen.
  8. Patients progressing on LHRH agonist plus an anti-androgen as first line therapy must be off anti-androgen for 4 weeks prior to first treatment with testosterone.
  9. Patients with rising PSA on two successive measurements at least two weeks apart.
  10. For Cohort A (enzalutamide) and Cohort B (abiraterone acetate):

    1. Prior treatment with up to 2 additional second line hormone therapies, including ketoconazole is allowed.
    2. Patients who have progressed on both enzalutamide and abiraterone acetate are eligible and post-BAT will be retreated with the last second line agent they had received (e.g. patient receiving abiraterone then enzalutamide would receive retreatment with enzalutamide post-BAT).
    3. Patients must be withdrawn from enzalutamide or abiraterone acetate for ≥ 4 weeks and have documented PSA increase after the withdrawal period.
    4. Patients receiving prednisone in conjunction with abiraterone acetate must be weaned off prednisone prior to starting BAT.
  11. For Cohort C (castration-only):

    1. Patients must continue on castrating therapy throughout BAT treatment.
    2. No prior second line hormone treatment with flutamide, bicalutamide, nilutamide, enzalutamide, abiraterone, ketoconazole, ARN-509 or other investigational androgen ablative therapies is permitted for Cohort C.
  12. Prior docetaxel for hormone-sensitive prostate cancer is permitted if ≤ 6 doses were given in conjunction with first-line androgen deprivation therapy and >12 months since last dose of docetaxel.
  13. Acceptable liver function:

    1. Bilirubin < 2.5 times institutional upper limit of normal (ULN)
    2. AST (SGOT) and ALT (SGPT) < 2.5 times ULN
  14. Acceptable renal function:

    a. Serum creatinine < 2.5 times ULN, OR

  15. Acceptable hematologic status:

    1. Absolute neutrophil count (ANC) ≥ 1500 cells/mm3 (1.5 ×109/L)
    2. Platelet count ≥ 100,000 platelet/mm3 (100 ×109/L)
    3. Hemoglobin ≥ 9 g/dL.
  16. At least 4 weeks since prior surgery with full recovery (no persistent toxicity ≥ Grade 1).
  17. Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

  1. Pain due to metastatic prostate cancer requiring opioid analgesics.
  2. >5 sites of visceral disease in lung or liver (nonspecific lung nodules ≤1 cm in diameter are permitted).
  3. Prior treatment with docetaxel or cabazitaxel for metastatic castration-resistant prostate cancer is prohibited.
  4. Requires urinary catheterization for voiding due to obstruction secondary to prostatic enlargement thought to be due to prostate cancer or benign prostatic hyperplasia.
  5. Evidence of disease in sites or extent that, in the opinion of the investigator, would put the patient at risk from therapy with testosterone (e.g. femoral metastases with concern over fracture risk, spinal metastases with concern over spinal cord compression, lymph node disease with concern for ureteral obstruction).
  6. Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study.
  7. Active uncontrolled infection, including known history of AIDS or hepatitis B or C.
  8. Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule.
  9. Prior history of a thromboembolic event within the last two years and not currently on systemic anticoagulation.
  10. Hematocrit >50%, untreated severe obstructive sleep apnea, uncontrolled or poorly controlled heart failure [per Endocrine Society Clinical Practice Guidelines (67)].

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02090114


Contacts
Layout table for location contacts
Contact: Irina Rifkind, RN, MSN 410-502-2043 irifkin1@jhmi.edu
Contact: Rana Sullivan, RN, BSN 410-614-6337 tomalra@jhmi.edu

Locations
Layout table for location information
United States, Maryland
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting
Baltimore, Maryland, United States, 21231
Contact: Irina Rifkind, RN, MSN    410-502-2043    irifkin1@jhmi.edu   
Contact: Rana Sullivan, RN, BSN    410-614-6337    tomalra@jhmi.edu   
Principal Investigator: Samuel Denmeade, MD         
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Samuel Denmeade, MD Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ClinicalTrials.gov Identifier: NCT02090114     History of Changes
Other Study ID Numbers: J1416
NA_00093344 ( Other Identifier: JHM IRB )
1R01CA184012-01 ( U.S. NIH Grant/Contract )
First Posted: March 18, 2014    Key Record Dates
Last Update Posted: May 14, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins:
Bipolar Androgen Therapy
Testosterone
Enzalutamide
Abiraterone
Androgen Ablative Therapies

Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Methyltestosterone
Abiraterone Acetate
Testosterone
Testosterone undecanoate
Testosterone enanthate
Testosterone 17 beta-cypionate
Androgens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hormone Antagonists
Cytochrome P-450 Enzyme Inhibitors